Deprescribing in psychopharmacology: what is the risk versus reward?

INTRODUCTION: Deprescribing, the systematic reduction or discontinuation of psychotropic medications when risks outweigh benefits or treatment no longer serves its goals, has attracted increasing attention. However, empirical evidence and guidance remain limited across medication classes. AREAS COVERED: Building on recent consensus statements, this expert opinion examines unresolved questions: prioritizing deprescribing in complex regimens, distinguishing withdrawal or rebound from recurrence, adapting tapering schedules, defining success through symptoms and patient-centered functioning, and integrating psychosocial support, measurement-based care, and contingency planning. We propose a cross-diagnostic approach distinguishing dose optimization, discontinuation after goal attainment, harm reduction, discontinuation for inefficacy, polypharmacy rationalization, and personalized therapeutic approaches. EXPERT OPINION: Deprescribing should form part of recurring pharmacotherapy reassessment. A 'review and reconsider' stance supports evaluation of each medication's continuing purpose, benefits, and burdens. Although consensus supports regimen review, adherence assessment, monitoring, and shared decisions, clinicians differ regarding tapering pace, medication redundancy, and balancing relapse risk against long-term adverse effects. Individual circumstances preclude universal tapering rules. Decisions should specify why treatment is reconsidered, assess withdrawal and relapse risks, monitor symptoms and functioning, provide psychosocial support, and establish when to pause, reverse, or modify the plan. Medication continuation should likewise represent a documented, active therapeutic decision made with patients.

Authors

Institutions

Publication Details

Journal
Expert Opinion on Pharmacotherapy
Published
2026-11-18
DOI
https://doi.org/10.1080/14656566.2026.2763342
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Deprescribing in psychopharmacology: what is the risk versus reward?

Joseph F. Goldberg, Manisha Kumari Jha, Snoben Kuruvila
2 links
Expert Opinion on Pharmacotherapy
Pharmaceutical Practices and Patient Outcomes
article

Deprescribing in psychopharmacology: what is the risk versus reward?

Joseph F. Goldberg, Manisha Kumari Jha, Snoben Kuruvila
article en

Abstract

INTRODUCTION: Deprescribing, the systematic reduction or discontinuation of psychotropic medications when risks outweigh benefits or treatment no longer serves its goals, has attracted increasing attention. However, empirical evidence and guidance remain limited across medication classes. AREAS COVERED: Building on recent consensus statements, this expert opinion examines unresolved questions: prioritizing deprescribing in complex regimens, distinguishing withdrawal or rebound from recurrence, adapting tapering schedules, defining success through symptoms and patient-centered functioning, and integrating psychosocial support, measurement-based care, and contingency planning. We propose a cross-diagnostic approach distinguishing dose optimization, discontinuation after goal attainment, harm reduction, discontinuation for inefficacy, polypharmacy rationalization, and personalized therapeutic approaches. EXPERT OPINION: Deprescribing should form part of recurring pharmacotherapy reassessment. A 'review and reconsider' stance supports evaluation of each medication's continuing purpose, benefits, and burdens. Although consensus supports regimen review, adherence assessment, monitoring, and shared decisions, clinicians differ regarding tapering pace, medication redundancy, and balancing relapse risk against long-term adverse effects. Individual circumstances preclude universal tapering rules. Decisions should specify why treatment is reconsidered, assess withdrawal and relapse risks, monitor symptoms and functioning, provide psychosocial support, and establish when to pause, reverse, or modify the plan. Medication continuation should likewise represent a documented, active therapeutic decision made with patients.

Expert Opinion on Pharmacotherapy
The University of Texas Southwestern Medical Center (US), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon